Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Organogenesis Holdings Inc’s stock clocked out at $4.50, down -3.64% from its previous closing price of $4.67. In other words, the price has decreased by -$3.64 from its previous closing price. On the day, 1.43 million shares were traded. ORGO stock price reached its highest trading level at $4.6799 during the session, while it also had its lowest trading level at $4.445.
Ratios:
To gain a deeper understanding of ORGO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 136.54. For the most recent quarter (mrq), Quick Ratio is recorded 3.35 and its Current Ratio is at 3.69. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on June 28, 2024, initiated with a Buy rating and assigned the stock a target price of $5.
On February 07, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.Morgan Stanley initiated its Equal-Weight rating on June 15, 2023, with a $5 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Driscoll Michael Joseph bought 25,000 shares for $5.08 per share.
Driscoll Michael Joseph sold 25,000 shares of ORGO for $127,535 on Mar 04 ’25. The Director now owns 166,879 shares after completing the transaction at $5.10 per share. On Dec 13 ’24, another insider, Gillheeney Gary S., who serves as the President and CEO of the company, sold 55,615 shares for $3.36 each. As a result, the insider received 186,866 and left with 3,044,779 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ORGO now has a Market Capitalization of 570726016 and an Enterprise Value of 600577408. As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 803.57, and their Forward P/E ratio for the next fiscal year is 24.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.18 while its Price-to-Book (P/B) ratio in mrq is 2.15. Its current Enterprise Value per Revenue stands at 1.246 whereas that against EBITDA is 15.582.
Stock Price History:
The Beta on a monthly basis for ORGO is 1.76, which has changed by 0.6071428 over the last 52 weeks, in comparison to a change of 0.06429911 over the same period for the S&P500. Over the past 52 weeks, ORGO has reached a high of $6.71, while it has fallen to a 52-week low of $2.16. The 50-Day Moving Average of the stock is 7.02%, while the 200-Day Moving Average is calculated to be 35.22%.
Shares Statistics:
It appears that ORGO traded 1.79M shares on average per day over the past three months and 1300360 shares per day over the past ten days. A total of 125.73M shares are outstanding, with a floating share count of 64.38M. Insiders hold about 49.24% of the company’s shares, while institutions hold 49.46% stake in the company. Shares short for ORGO as of 1741910400 were 8615328 with a Short Ratio of 4.81, compared to 1739491200 on 8666323. Therefore, it implies a Short% of Shares Outstanding of 8615328 and a Short% of Float of 28.78.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
